ABI Positions Itself as a Technology Consultant; Plans to Introduce LC/MALDI-TOF Mass Spec | GenomeWeb

When it comes to integrating proteomics with its other offerings, Applied Biosystems is considering taking a page out of another three-letter heavyweight's playbook: like IBM, ABI is moving toward a consulting-oriented business model for customers whose needs span the proteomics as well as gene expression space, ABI executives said last week at the Drug Discovery Technology conference.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.